If you'd invested $10,000 in (NASDAQ: NVAX) a year ago, you would have made a risky bet. That's because the biotech company had issued a going concern earlier this year. This warning meant that, if uncertainty persisted, the company might have had to shut down.

Prior to that, Novavax, a star earlier in the pandemic, saw its shares drop more than 90% from their peak. The company's coronavirus vaccine reached the market late and missed out on the biggest revenue opportunities, disappointing investors.

Along with the going concern, Novavax launched a major cost-cutting plan. Considering all of this, how did your $10,000 investment turn out?

Continue reading

Source Fool.com